文献速递银屑病与炎症性皮肤病

阿达木单抗治疗药物监测在银屑病中的真实世界实施与结局:一国级专科中心的经验

Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience.
PubMed 文献 · J Invest Dermatol · 2023-03-07

该研究在一国级银屑病专科服务中引入阿达木单抗治疗药物监测(TDM),并以RE-AIM框架评估实施效果。5个月内229例接受阿达木单抗治疗者中170例(74%)接受了TDM。TDM指导的剂量递增使血清药物浓度<8.3 μg/ml的15例无应答者中13例(87%)临床改善,中位PASI下降3.2(四分位距=2.2-8.2),历时23.4周。作者认为基于务实血清采样的阿达木单抗TDM临床可行,可能带来患者获益。

要点

  • 5个月内229例阿达木单抗治疗者中170例(74%)接受了TDM。
  • 血清浓度<8.3 μg/ml的15例无应答者中13例(87%)在TDM指导剂量递增后临床改善。
  • 5例皮损清除者经主动TDM调整剂量,4例(80%)在50周(范围=42-52)后维持皮损清除。

核心结论

  • 基于务实血清采样的阿达木单抗TDM临床可行,可能带来患者获益。
  • 情境化的实施干预与系统化实施评估可能弥合生物标志物研究与实践之间的差距。

研究设计与样本

  • 在一国级专科银屑病服务中引入阿达木单抗TDM,采用RE-AIM(可及性、有效性、采纳性、实施性、维持性)实施科学框架进行评估。
  • 实施前进行规划(验证本地检测方法),并针对患者(常规复诊时务实采样)、临床医生(引入TDM方案)和医疗系统(将阿达木单抗TDM作为关键绩效指标)实施干预。
  • 研究周期为5个月。

主要发现

  • 5个月内,229例接受阿达木单抗治疗的个体中170例(74%)接受了TDM。
  • 血清药物浓度<8.3 μg/ml的15例无应答者中,13例(87%)在TDM指导的剂量递增后出现临床改善,23.4周后中位PASI下降3.2(四分位距=2.2-8.2)。
  • 因药物浓度超治疗水平(>8.3 μg/ml;n=2)或抗药抗体阳性(n=2)而接受TDM指导的生物制剂转换的无应答者均出现临床改善,20.0周后PASI下降7.8(四分位距=7.5-12.9)。
  • 主动TDM使5例皮损清除且药物浓度低于或高于治疗水平的个体得以减量;其中4例(80%)在50周(范围=42-52)后维持皮损清除。

关键数值与推荐

  • 血清阿达木单抗浓度<8.3 μg/ml的无应答者接受TDM指导的剂量递增。
  • 血清阿达木单抗浓度>8.3 μg/ml或抗药抗体阳性的无应答者接受TDM指导的生物制剂转换。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Serum adalimumab concentration is a biomarker of treatment response but therapeutic drug monitoring (TDM) is yet to be implemented in routine psoriasis care. We incorporated adalimumab TDM in a national specialized psoriasis service and evaluated it using the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) implementation science framework. We undertook pre-implementation planning (validating local assays) and implementation interventions targeted to patients (pragmatic sampling at routine reviews), clinicians (introduction of a TDM protocol), and healthcare systems (adalimumab TDM as a key performance indicator). Over 5 months, 170 of 229 (74%) individuals treated with adalimumab received TDM. Clinical improvement after TDM-guided dose escalation occurred in 13 of 15 (87%) nonresponders with serum drug concentrations <8.3 μg/ml (median PASI reduction of 3.2 [interquartile range = 2.2-8.2] after 23.4 weeks) and in all nonresponders who had TDM-guided switch in biologic due to supratherapeutic drug concentrations (>8.3 μg/ml; n = 2) or positive antidrug antibody (n = 2) (PASI reduction of 7.8 [interquartile range = 7.5-12.9] after 20.0 weeks). Proactive TDM led to dose reduction in five individuals with clear skin and subtherapeutic or supratherapeutic drug concentrations; four (80%) sustained clear skin after 50 weeks (range = 42-52). Adalimumab TDM based on pragmatic serum sampling is clinically viable and may lead to patient benefit. Context-specific implementation interventions and systematic implementation assessment may bridge the biomarker research-to-practice gap.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Raharja A, Arkir Z, Rinaldi G, et al. Real-World Implementation and Outcomes of Adalimumab Therapeutic Drug Monitoring in Psoriasis: A National Specialized Center Experience. J Invest Dermatol. 2023. PMID: 36889663. doi:10.1016/j.jid.2023.01.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。